Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
22 May 2017
E-001460/2017
Answer given by Mr Moedas on behalf of the Commission

The Commission is fully aware of the priority pathogens list recently published by the World Health Organisation (WHO).

It supports research on Anti-Microbial Resistance (AMR) since 1999 with an investment of over EUR 1.3 billion. Research is currently ongoing in the areas of health, veterinary sciences, food and environment. The focus is on antimicrobials, vaccines and alternative therapies to treat infections caused by the pathogenic bacteria on the WHO list and also other relevant bacteria like Mycobacterium tuberculosis.

The Commission is using different instruments to support the development of new antimicrobials, such as Innovative Medicines Initiative (IMI)(1), which is the world’s biggest public‐private partnership in the field of AMR. IMI's new drugs for bad bugs programme has already invested over EUR 650 million, created a drug discovery platform for testing and optimising new antibiotics, and established a Pan-European network of more than 700 hospitals and 500 laboratories in 39 countries.

Through calls-for-research specifically targeted at Small and Medium-sized Enterprises (SMEs), the Commission has strengthened European SMEs involved in AMR research.

Furthermore, the Commission and the European Investment Bank launched InnovFin ID(2) that provides loans to help develop new solutions for infectious diseases such as a HIV monitoring device, a diagnostic tool, and clinical trials of treatments for hepatitis B, human papilloma virus-induced cancers, and tuberculosis.

Efforts are being further stepped up with the preparation of a second EU Action Plan planned to be finalised by summer 2017 to support Member States in the fight against AMR. A public consultation(3) collecting the views and input of citizens, administrations, associations and other organisations on possible activities to include in the new Action Plan closed on 28 April 2017.

(1)http://www.imi.europa.eu/ A joint undertaking between the EU and the European Federation of pharmaceutical industries and associations (EFPIA, http://efpia.eu)
(2)http://www.eib.org/attachments/documents/innovfin_infectious_diseases_flysheet_en.pdf
(3)http://ec.europa.eu/dgs/health_food-safety/amr/consultations/consultation_20170123_amr-new-action-plan_en.htm

Last updated: 30 May 2017Legal notice